Arbutus Biopharma Corp(ABUS)stock report

Arbutus Biopharma Corp is a Canada-based biopharmaceutical company. The Company is dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company develops a portfolio of drug candidates with multiple mechanisms of action that results in a combination therapy to cure HBV. In addition to its HBV pipeline, the Company actively licenses its Lipid Nanoparticle (LNP) technology to its industry partners. This technology represents a delivery technology in RNA interference (RNAi) therapeutic development, which has enabled several clinical trials and has been administered to hundreds of human subjects.

Highlights: phase I stage company

Market Cap: 212M; Shares Outstanding:63.3M; Short Interest: 1.55%; Q1 2019(3/31/19): Cash 90.08M. Loss 84.96M

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 -1.21 22.44% -44.05%
2019.3.31 -0.47 -30.56% 61.16%
2019.6.30 -0.92 -162.86% -95.74%
2019.9.30 -2.48 -189.29% -169.57%


Date Sales % last year % last quarter
2018.12.31 5.95M -44.44% 39.34%
2019.3.31 0.68M -52.72% -88.57%
2019.6.30 1.83M -50.30% 169.12%
2019.9.30 4.39M 2.95% 139.89%


Insider Transactions:

Institution Ownership:

Total institutions: 68,Reduced 1
Shares hold: 20962k shares. Reduced 1051k
shares% hold: 33.75%,decreased by 1.69%

Analyst Ratings:

* News:

2019.10.08: Arbutus Biopharma (ABUS) Investor Presentation – Slideshow

Leave a Reply